{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Optune%28NOVOTTF-100A%29",
    "query": {
      "intervention": "Optune(NOVOTTF-100A)"
    },
    "page_size": 10
  },
  "pagination": {
    "page": 1,
    "page_size": 10,
    "total_count": 41,
    "total_pages": 5,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Optune%28NOVOTTF-100A%29&page=2&page_size=10",
    "previous_page_url": null
  },
  "source": "remote",
  "last_synced_at": "2026-09-27T16:39:24.855Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT04474353",
      "title": "Study of Tumor Treating Fields With Hypofractionated Chemoradiotherapy in Newly Diagnosed Glioblastoma",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Glioblastoma",
        "Newly Diagnosed Glioblastoma"
      ],
      "interventions": [
        {
          "name": "Optune",
          "type": "DEVICE"
        },
        {
          "name": "Gadolinium",
          "type": "DRUG"
        },
        {
          "name": "Temozolomide",
          "type": "DRUG"
        },
        {
          "name": "Stereotactic radiosurgery (SRS)",
          "type": "RADIATION"
        }
      ],
      "intervention_types": [
        "DEVICE",
        "DRUG",
        "RADIATION"
      ],
      "sponsor": "Stanford University",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 12,
      "start_date": "2021-05-21",
      "completion_date": "2025-09-02",
      "has_results": false,
      "last_update_posted_date": "2025-12-26",
      "last_synced_at": "2026-09-27T16:39:24.855Z",
      "location_count": 1,
      "location_summary": "Stanford, California",
      "locations": [
        {
          "city": "Stanford",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04474353"
    },
    {
      "nct_id": "NCT02441322",
      "title": "Evaluating Therapeutic Response to Novo-TTF",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Glioblastoma Multiforme"
      ],
      "interventions": [
        {
          "name": "Novo-TTF",
          "type": "DEVICE"
        }
      ],
      "intervention_types": [
        "DEVICE"
      ],
      "sponsor": "Abramson Cancer Center at Penn Medicine",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 30,
      "start_date": "2014-12",
      "completion_date": "2023-12",
      "has_results": false,
      "last_update_posted_date": "2024-07-19",
      "last_synced_at": "2026-09-27T16:39:24.855Z",
      "location_count": 1,
      "location_summary": "Philadelphia, Pennsylvania",
      "locations": [
        {
          "city": "Philadelphia",
          "state": "Pennsylvania"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02441322"
    },
    {
      "nct_id": "NCT02663271",
      "title": "TTFields and Pulsed Bevacizumab for Recurrent Glioblastoma",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Glioblastoma Multiforme",
        "Glioblastoma",
        "Malignant Glioma",
        "GBM"
      ],
      "interventions": [
        {
          "name": "Bevacizumab",
          "type": "DRUG"
        },
        {
          "name": "Optune",
          "type": "DEVICE"
        },
        {
          "name": "Brain MRI",
          "type": "OTHER"
        },
        {
          "name": "Quality of Life Questionnaires",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "DRUG",
        "DEVICE",
        "OTHER"
      ],
      "sponsor": "University of Florida",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "22 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "22 Years and older"
      },
      "enrollment_count": 10,
      "start_date": "2016-12-19",
      "completion_date": "2021-06-11",
      "has_results": true,
      "last_update_posted_date": "2022-06-23",
      "last_synced_at": "2026-09-27T16:39:24.855Z",
      "location_count": 2,
      "location_summary": "Gainesville, Florida • St Louis, Missouri",
      "locations": [
        {
          "city": "Gainesville",
          "state": "Florida"
        },
        {
          "city": "St Louis",
          "state": "Missouri"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02663271"
    },
    {
      "nct_id": "NCT03430791",
      "title": "Trial of Combination Tumor Treating Fields (TTF; Optune), Nivolumab Plus/Minus Ipilimumab for Recurrent Glioblastoma",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Recurrent Glioblastoma"
      ],
      "interventions": [
        {
          "name": "Nivolumab 240 mg IV",
          "type": "DRUG"
        },
        {
          "name": "Nivolumab 3 mg/kg",
          "type": "DRUG"
        },
        {
          "name": "Ipilimumab 1 mg/kg",
          "type": "DRUG"
        },
        {
          "name": "NovoTTF200A (Optune)",
          "type": "DEVICE"
        }
      ],
      "intervention_types": [
        "DRUG",
        "DEVICE"
      ],
      "sponsor": "Baptist Health South Florida",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 5,
      "start_date": "2018-12-05",
      "completion_date": "2021-01-27",
      "has_results": true,
      "last_update_posted_date": "2023-02-02",
      "last_synced_at": "2026-09-27T16:39:24.855Z",
      "location_count": 1,
      "location_summary": "Miami, Florida",
      "locations": [
        {
          "city": "Miami",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03430791"
    },
    {
      "nct_id": "NCT02847559",
      "title": "Optune Delivered Electric Field Therapy and Bevacizumab in Treating Patients With Recurrent or Progressive Grade 2 or 3 Meningioma",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Anaplastic (Malignant) Meningioma",
        "Atypical Meningioma",
        "Grade II Meningioma",
        "Grade III Meningioma",
        "Recurrent Meningioma",
        "Supratentorial Meningioma"
      ],
      "interventions": [
        {
          "name": "Bevacizumab",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Electric Field Therapy",
          "type": "PROCEDURE"
        },
        {
          "name": "NovoTTF-200A Device",
          "type": "DEVICE"
        },
        {
          "name": "Quality-of-Life Assessment",
          "type": "PROCEDURE"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "PROCEDURE",
        "DEVICE"
      ],
      "sponsor": "Northwestern University",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 20,
      "start_date": "2016-08-01",
      "completion_date": "2026-05-01",
      "has_results": false,
      "last_update_posted_date": "2026-09-09",
      "last_synced_at": "2026-09-27T16:39:24.855Z",
      "location_count": 8,
      "location_summary": "Santa Monica, California • Miami, Florida • Atlanta, Georgia + 5 more",
      "locations": [
        {
          "city": "Santa Monica",
          "state": "California"
        },
        {
          "city": "Miami",
          "state": "Florida"
        },
        {
          "city": "Atlanta",
          "state": "Georgia"
        },
        {
          "city": "Chicago",
          "state": "Illinois"
        },
        {
          "city": "Lake Forest",
          "state": "Illinois"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02847559"
    },
    {
      "nct_id": "NCT03232424",
      "title": "NovoTTF-200A and Temozolomide Chemoradiation for Newly Diagnosed Glioblastoma",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Glioblastoma, Adult"
      ],
      "interventions": [
        {
          "name": "NovoTTF-200A",
          "type": "DEVICE"
        },
        {
          "name": "Temozolomide",
          "type": "DRUG"
        },
        {
          "name": "3D conformal or intensity modulated radiation therapy (IMRT)",
          "type": "RADIATION"
        }
      ],
      "intervention_types": [
        "DEVICE",
        "DRUG",
        "RADIATION"
      ],
      "sponsor": "Hackensack Meridian Health",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 12,
      "start_date": "2017-07-26",
      "completion_date": "2022-12-07",
      "has_results": false,
      "last_update_posted_date": "2024-11-18",
      "last_synced_at": "2026-09-27T16:39:24.855Z",
      "location_count": 1,
      "location_summary": "Hackensack, New Jersey",
      "locations": [
        {
          "city": "Hackensack",
          "state": "New Jersey"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03232424"
    },
    {
      "nct_id": "NCT03128047",
      "title": "HUMC 1612: Optune NovoTTF-200A System",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "High Grade Glioma",
        "Ependymoma"
      ],
      "interventions": [
        {
          "name": "Optune NovoTTF-200A System",
          "type": "DEVICE"
        }
      ],
      "intervention_types": [
        "DEVICE"
      ],
      "sponsor": "Hackensack Meridian Health",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "5 Years",
        "maximum_age": "21 Years",
        "sex": "ALL",
        "summary": "5 Years to 21 Years"
      },
      "enrollment_count": 7,
      "start_date": "2017-04-06",
      "completion_date": "2025-04-05",
      "has_results": true,
      "last_update_posted_date": "2025-07-08",
      "last_synced_at": "2026-09-27T16:39:24.855Z",
      "location_count": 2,
      "location_summary": "Orlando, Florida • Hackensack, New Jersey",
      "locations": [
        {
          "city": "Orlando",
          "state": "Florida"
        },
        {
          "city": "Hackensack",
          "state": "New Jersey"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03128047"
    },
    {
      "nct_id": "NCT03705351",
      "title": "Tumor Treating Fields With Chemoradiation in Newly Diagnosed GBM",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Glioblastoma",
        "Cancer of Brain",
        "Glioblastoma Multiforme",
        "Brain Tumor"
      ],
      "interventions": [
        {
          "name": "Tumor Treating Fields",
          "type": "DEVICE"
        },
        {
          "name": "Temozolomide",
          "type": "DRUG"
        },
        {
          "name": "Radiation Therapy",
          "type": "RADIATION"
        }
      ],
      "intervention_types": [
        "DEVICE",
        "DRUG",
        "RADIATION"
      ],
      "sponsor": "Providence Health & Services",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "22 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "22 Years and older"
      },
      "enrollment_count": 7,
      "start_date": "2019-12-02",
      "completion_date": "2022-02-24",
      "has_results": true,
      "last_update_posted_date": "2024-03-04",
      "last_synced_at": "2026-09-27T16:39:24.855Z",
      "location_count": 2,
      "location_summary": "San Francisco, California • Portland, Oregon",
      "locations": [
        {
          "city": "San Francisco",
          "state": "California"
        },
        {
          "city": "Portland",
          "state": "Oregon"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03705351"
    },
    {
      "nct_id": "NCT06061809",
      "title": "N-803 and PD-L1 t-haNK Combined With Bevacizumab for Recurrent or Progressive Glioblastoma",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Glioblastoma"
      ],
      "interventions": [
        {
          "name": "Bevacizumab",
          "type": "DRUG"
        },
        {
          "name": "PD-L1 t-haNK",
          "type": "DRUG"
        },
        {
          "name": "N-803",
          "type": "DRUG"
        },
        {
          "name": "Tumor Treating Fields (TTFields, 200 kHz)",
          "type": "DEVICE"
        }
      ],
      "intervention_types": [
        "DRUG",
        "DEVICE"
      ],
      "sponsor": "ImmunityBio, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 34,
      "start_date": "2024-08-07",
      "completion_date": "2030-12-31",
      "has_results": false,
      "last_update_posted_date": "2026-07-01",
      "last_synced_at": "2026-09-27T16:39:24.855Z",
      "location_count": 4,
      "location_summary": "El Segundo, California • Fullerton, California • Newport Beach, California + 1 more",
      "locations": [
        {
          "city": "El Segundo",
          "state": "California"
        },
        {
          "city": "Fullerton",
          "state": "California"
        },
        {
          "city": "Newport Beach",
          "state": "California"
        },
        {
          "city": "Nashville",
          "state": "Tennessee"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06061809"
    },
    {
      "nct_id": "NCT03906448",
      "title": "FORWARD Optune and Adjuvant TMZ in Grade II/III Astrocytoma",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Astrocytoma, Grade II",
        "Astrocytoma, Grade III"
      ],
      "interventions": [
        {
          "name": "TTFields with adjuvant temozolomide",
          "type": "COMBINATION_PRODUCT"
        }
      ],
      "intervention_types": [
        "COMBINATION_PRODUCT"
      ],
      "sponsor": "University of Florida",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "99 Years",
        "sex": "ALL",
        "summary": "18 Years to 99 Years"
      },
      "enrollment_count": 1,
      "start_date": "2019-05-20",
      "completion_date": "2020-06-08",
      "has_results": true,
      "last_update_posted_date": "2021-09-23",
      "last_synced_at": "2026-09-27T16:39:24.855Z",
      "location_count": 5,
      "location_summary": "Gainesville, Florida • Tampa, Florida • Detroit, Michigan + 2 more",
      "locations": [
        {
          "city": "Gainesville",
          "state": "Florida"
        },
        {
          "city": "Tampa",
          "state": "Florida"
        },
        {
          "city": "Detroit",
          "state": "Michigan"
        },
        {
          "city": "Providence",
          "state": "Rhode Island"
        },
        {
          "city": "Houston",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03906448"
    }
  ]
}